44,462 Shares in Bristol Myers Squibb Company $BMY Purchased by M Holdings Securities Inc.

M Holdings Securities Inc. acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 44,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,398,000.

Several other institutional investors also recently bought and sold shares of the company. Zions Bancorporation National Association UT boosted its holdings in shares of Bristol Myers Squibb by 21.7% during the 4th quarter. Zions Bancorporation National Association UT now owns 6,826 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 1,219 shares during the last quarter. GWN Securities Inc. boosted its holdings in shares of Bristol Myers Squibb by 6.9% during the 4th quarter. GWN Securities Inc. now owns 15,138 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 973 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Bristol Myers Squibb by 11.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 720,934 shares of the biopharmaceutical company’s stock worth $38,887,000 after purchasing an additional 72,244 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. boosted its holdings in shares of Bristol Myers Squibb by 113.7% during the 4th quarter. Financiere des Professionnels Fonds d investissement inc. now owns 138,021 shares of the biopharmaceutical company’s stock worth $7,445,000 after purchasing an additional 73,425 shares during the last quarter. Finally, First American Trust FSB acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $314,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BMY shares. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Bank of America lowered their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Stock Down 1.5%

BMY stock opened at $55.62 on Thursday. The firm has a market cap of $113.58 billion, a PE ratio of 15.62, a PEG ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm’s 50 day moving average price is $57.90 and its 200-day moving average price is $56.79. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.